- Home
- CRT vs INKT Comparison
CRT vs INKT Comparison
Compare CRT & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | INKT |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United States | United States |
| Employees | 2 | N/A |
| Industry | Oil & Gas Production | Medicinal Chemicals and Botanical Products |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.1M | 53.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | CRT | INKT |
|---|---|---|
| Price | $9.66 | $10.77 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | ★ 20.6K | 13.8K |
| Earning Date | 04-14-2026 | 05-15-2026 |
| Dividend Yield | ★ 5.29% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.07 | $8.48 |
| 52 Week High | $11.10 | $21.50 |
Technical Indicators
Market Signals| Indicator | CRT | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 43.35 |
| Support Level | $9.29 | $9.47 |
| Resistance Level | $10.11 | $12.61 |
| Average True Range (ATR) | 0.26 | 0.58 |
| MACD | 0.14 | -0.07 |
| Stochastic Oscillator | 82.08 | 20.05 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.